JP2020500511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500511A5 JP2020500511A5 JP2019526306A JP2019526306A JP2020500511A5 JP 2020500511 A5 JP2020500511 A5 JP 2020500511A5 JP 2019526306 A JP2019526306 A JP 2019526306A JP 2019526306 A JP2019526306 A JP 2019526306A JP 2020500511 A5 JP2020500511 A5 JP 2020500511A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- tgf
- monomer
- amino acid
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000178 monomer Substances 0.000 claims description 80
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 58
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 58
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 58
- 238000006467 substitution reaction Methods 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 125000000539 amino acid group Chemical group 0.000 claims description 37
- 108020001507 fusion proteins Proteins 0.000 claims description 30
- 102000037865 fusion proteins Human genes 0.000 claims description 30
- 230000011664 signaling Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000004475 Arginine Substances 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 239000004472 Lysine Substances 0.000 claims description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 21
- 235000004279 alanine Nutrition 0.000 claims description 20
- 230000002159 abnormal effect Effects 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 150000001294 alanine derivatives Chemical class 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims description 6
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 150000002614 leucines Chemical class 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 208000037176 hereditary disorder of connective tissue Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 3
- 150000002519 isoleucine derivatives Chemical class 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 2
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 102000034287 fluorescent proteins Human genes 0.000 claims description 2
- 108091006047 fluorescent proteins Proteins 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021214183A JP7623273B2 (ja) | 2016-11-18 | 2021-12-28 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
| JP2023160199A JP2023164748A (ja) | 2016-11-18 | 2023-09-25 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423920P | 2016-11-18 | 2016-11-18 | |
| US62/423,920 | 2016-11-18 | ||
| PCT/US2017/062233 WO2018094173A1 (en) | 2016-11-18 | 2017-11-17 | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021214183A Division JP7623273B2 (ja) | 2016-11-18 | 2021-12-28 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500511A JP2020500511A (ja) | 2020-01-16 |
| JP2020500511A5 true JP2020500511A5 (enExample) | 2020-11-19 |
| JP7079779B2 JP7079779B2 (ja) | 2022-06-02 |
Family
ID=62146703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526306A Active JP7079779B2 (ja) | 2016-11-18 | 2017-11-17 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
| JP2021214183A Active JP7623273B2 (ja) | 2016-11-18 | 2021-12-28 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
| JP2023160199A Withdrawn JP2023164748A (ja) | 2016-11-18 | 2023-09-25 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021214183A Active JP7623273B2 (ja) | 2016-11-18 | 2021-12-28 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
| JP2023160199A Withdrawn JP2023164748A (ja) | 2016-11-18 | 2023-09-25 | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11091523B2 (enExample) |
| EP (1) | EP3541409B1 (enExample) |
| JP (3) | JP7079779B2 (enExample) |
| ES (1) | ES3011833T3 (enExample) |
| PT (1) | PT3541409T (enExample) |
| WO (1) | WO2018094173A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11091523B2 (en) * | 2016-11-18 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Engineered TGF-β monomers and their use for inhibiting TGF-β signaling |
| WO2021101796A1 (en) * | 2019-11-18 | 2021-05-27 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| CA3162431A1 (en) * | 2020-01-21 | 2021-07-29 | Augustinus Bader | Cosmetic formulation for topical administration comprising novel peptides that improve appearance and regeneration of skin |
| JP2023539195A (ja) * | 2020-08-27 | 2023-09-13 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用 |
| EP4269429A4 (en) * | 2020-12-23 | 2025-07-30 | Korea Inst Sci & Tech | NEW PEPTIDE CAPABLE OF INHIBITING TGF-BETA SIGNALING AND ITS UTILIZATION |
| WO2023064747A1 (en) * | 2021-10-11 | 2023-04-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Engineered tgf-beta monomers and methods of use |
| JP2024096518A (ja) * | 2023-01-03 | 2024-07-16 | エフビーデー バイオロジクス リミテッド | 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法 |
| WO2024163457A2 (en) * | 2023-01-30 | 2024-08-08 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Inducible cytokine transgenes for potentiated immune cell function |
| EP4490201A4 (en) | 2023-05-31 | 2026-03-11 | Fbd Biologics Ltd | CD47/PD-L1 Targeted Protein Complex and Its Methods of Use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| WO2005024035A1 (en) * | 2003-09-05 | 2005-03-17 | National Research Council Of Canada | Coiled-coil fusion proteins comprising cell receptor domains |
| WO2011094749A2 (en) * | 2010-02-01 | 2011-08-04 | Board Of Regents, The University Of Texas System | Small molecule inhibitors that block assembly of the tgf-beta signaling complex |
| CU24181B1 (es) * | 2012-11-09 | 2016-04-25 | Ct De Inmunología Molecular | POLIPÉPTIDOS DERIVADOS DEL TGFß |
| US11091523B2 (en) | 2016-11-18 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Engineered TGF-β monomers and their use for inhibiting TGF-β signaling |
-
2017
- 2017-11-17 US US16/461,747 patent/US11091523B2/en active Active
- 2017-11-17 JP JP2019526306A patent/JP7079779B2/ja active Active
- 2017-11-17 EP EP17871472.1A patent/EP3541409B1/en active Active
- 2017-11-17 ES ES17871472T patent/ES3011833T3/es active Active
- 2017-11-17 WO PCT/US2017/062233 patent/WO2018094173A1/en not_active Ceased
- 2017-11-17 PT PT178714721T patent/PT3541409T/pt unknown
-
2021
- 2021-07-07 US US17/369,736 patent/US12428460B2/en active Active
- 2021-12-28 JP JP2021214183A patent/JP7623273B2/ja active Active
-
2023
- 2023-09-25 JP JP2023160199A patent/JP2023164748A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500511A5 (enExample) | ||
| CN111148756B (zh) | T细胞受体 | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| ES2983771T3 (es) | TCR de NY-ESO | |
| JP2025023990A (ja) | 複数ドメイン結合性分子 | |
| CN116723851A (zh) | 白介素-18变体和使用方法 | |
| ES3011833T3 (en) | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling | |
| WO2013036574A4 (en) | Modified forms of pseudomonas exotoxin a | |
| JP2012525847A (ja) | Ｆｇｆ２１変異体およびその使用 | |
| CN102007145A (zh) | 基于结合egfr的工程化蛋白质的靶向治疗剂 | |
| CN113056283A (zh) | 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 | |
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| KR20200006985A (ko) | 인간 알파 태아단백-특이적 t 세포 수용체 및 이의 용도 | |
| JP2023522799A (ja) | 特異的結合性分子 | |
| JP2024517884A (ja) | ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体 | |
| CN107206103A (zh) | 用于治疗目的的抗体‑脲酶缀合物 | |
| JP2018506287A5 (enExample) | ||
| JP2022527813A (ja) | Ｍａｇｅａ１特異的ｔ細胞受容体およびその使用 | |
| WO2019234187A1 (en) | Trimeric polypeptide complexes and uses thereof | |
| CN112533629A (zh) | 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法 | |
| TW202330589A (zh) | 治療 | |
| KR20130132429A (ko) | 모에신 조절제 및 그의 용도 | |
| JP2023532760A (ja) | 特異的結合分子 | |
| CA3146292A1 (en) | Mhc class ii molecules and methods of use thereof | |
| JP2023546269A (ja) | Ｔ細胞を増殖させるための二重特異性コンストラクトおよび関連する方法 |